Ozempic and Wegovy Drug Prices Under Scrutiny in Congressional Hearing
Tuesday, 24 September 2024, 07:17
Ozempic and Wegovy Pricing Analysis
During the recent congressional committee hearing, Novo Nordisk's CEO Lars Jørgensen defended the prices of Ozempic and Wegovy, which are significantly higher in the U.S. compared to other countries. This raises serious ethical questions regarding medication accessibility and patient treatment costs.
Key Highlights From the Hearing
- Jørgensen questioned about pricing strategies.
- Concerns over patient affordability expressed by numerous committee members.
- Global pricing disparities discussed, highlighting a broken healthcare model.
This hearing emphasized the increasing urgency for health policy reforms in prescription drug pricing.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.